[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536952":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":95,"collaborators":97,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":10,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":10,"maxAge":10,"enrollmentInfo":109,"targetDuration":112,"studyType":113,"phases":10,"briefSummary":114,"conditions":115,"keywords":10,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Genetix Biotherapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All Participants",null,"Participants with β-thalassemia treated with beti-cel in the post-marketing setting will be followed in this registry study for up to 15 years after infusion with beti-cel to collect real-world longitudinal data.",[13],"Other: No Intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","No Intervention","This is non-interventional study.",[9],[21],{"name":22,"affiliation":23,"role":24},"Himal Lal Thakar, MD","bluebird bio, Inc.","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"bluebird bio","CONTACT","+1-833-999-6378","clinicaltrials@bluebirdbio.com",[32,46,55,65,75,85],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":10},"UCSF Benioff Children's Hospitals","RECRUITING","Oakland","California","94609","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-122.2708,37.80437,{"lat":44,"lon":43},{"facility":47,"status":34,"city":48,"state":36,"zip":49,"country":38,"countryCode":39,"cosmosGeoPoint":50,"geoPoint":54,"contacts":10},"Stanford University","Palo Alto","94043",{"type":41,"coordinates":51},[52,53],-122.14302,37.44188,{"lat":53,"lon":52},{"facility":56,"status":34,"city":57,"state":58,"zip":59,"country":38,"countryCode":39,"cosmosGeoPoint":60,"geoPoint":64,"contacts":10},"University of Minnesota","Minneapolis","Minnesota","55455",{"type":41,"coordinates":61},[62,63],-93.26384,44.97997,{"lat":63,"lon":62},{"facility":66,"status":34,"city":67,"state":68,"zip":69,"country":38,"countryCode":39,"cosmosGeoPoint":70,"geoPoint":74,"contacts":10},"Cohen Children's Medical Center","New Hyde Park","New York","11040",{"type":41,"coordinates":71},[72,73],-73.68791,40.7351,{"lat":73,"lon":72},{"facility":76,"status":34,"city":77,"state":78,"zip":79,"country":38,"countryCode":39,"cosmosGeoPoint":80,"geoPoint":84,"contacts":10},"Children's Hospital of Philadelphia","Philadelphia","Pennsylvania","19104",{"type":41,"coordinates":81},[82,83],-75.16362,39.95238,{"lat":83,"lon":82},{"facility":86,"status":34,"city":87,"state":88,"zip":89,"country":38,"countryCode":39,"cosmosGeoPoint":90,"geoPoint":94,"contacts":10},"Texas Children's Hospital","Houston","Texas","77030",{"type":41,"coordinates":91},[92,93],-95.36327,29.76328,{"lat":93,"lon":92},{"type":96,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[98],{"name":99,"class":100},"Center for International Blood and Marrow Transplant Research","NETWORK","100536952","a-study-of-participants-with--thalassemia-treated-with-betibeglogene-autotemcel-100536952",false,"NCT06271512","A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel","A Safety and Effectiveness Registry Study of Patients with Β-Thalassemia Treated with Betibeglogene Autotemcel (the Glostar Registry)","Inclusion Criteria:\n\n* Participant must be treated with beti-cel in the post marketing setting at a center in the US that participates in the Registry.\n* Participant must sign an informed consent and\u002For assent prior to enrollment as required under applicable laws and regulations.\n* Participant must have signed an informed consent and\u002For assent permitting data to be shared with Center for International Blood and Marrow Transplant Research (CIBMTR).\n* Participant must be followed by a hematologist based in the US.\n\nExclusion Criteria:\n\n\\- There are no exclusion criteria for Registry participation.","ALL",{"count":110,"type":111},150,"ESTIMATED","15 Years","OBSERVATIONAL","The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.",[116],"Beta-Thalassemia","2025-02-10",{"date":119,"type":120},"2025-02-11","ACTUAL",{"date":122,"type":120},"2024-01-23",{"date":124,"type":111},"2043-12",{"name":5,"class":6},6]